Prostate Cancer | Specialty

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Enzalutamide Bests Bicalutamide in Two CRPC Studies

May 17th 2015

Enzalutamide significantly improved progression-free survival, PSA kinetics, and quality of life compared with bicalutamide in men with castration-resistant prostate cancer.

Dr. Brawer on Clinical Utility of CCP Test in Prostate Cancer

May 17th 2015

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.

Active Surveillance Protocols Needed for Prostate Cancer

May 16th 2015

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

Multiparametric MRI Avoids Many Biopsies, Misses a Few Cancers Compared With TRUS

May 16th 2015

Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.

Dr. Crawford on LHRH Agonists and GNRH Antagonists

May 16th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.

Dr. Benson on Extensive Biopsies for Low-Risk Prostate Cancer

May 11th 2015

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses extensive biopsies in low-risk patients with prostate cancer.

Novel Strategies Aimed at Overcoming Resistance to AR Therapy in Prostate Cancer

May 8th 2015

With increased understanding of the biology of CRPC and the mechanisms of action of AR-targeting drugs, researchers are developing a growing appreciation for the extensive heterogeneity and complexity of both prostate cancer and androgen signaling.

Clinical Development of Prostate Cancer Vaccines Continues

May 6th 2015

The field of prostate cancer vaccines remains an area of active exploration, with clinical trials into sipuleucel-T continuing even amid a corporate restructuring and a phase III study into PROSTVAC reaching full enrollment.

Dr. Michalski on Minimizing Long-Term Consequences of Radiation

May 5th 2015

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Walsh's Quest to Understand Male Anatomy Revolutionized the Prostatectomy

May 5th 2015

In 1974, Patrick C. Walsh, MD, took charge of the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland, and spent the next few decades refining the radical prostatectomy into a safe, effective, and tolerable procedure, one that has not only extended countless lives but has also preserved quality of life.

Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

May 2nd 2015

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.